DiaMedica Therapeutics Inc. DMAC
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a CNS/neurology/psychiatry drug developer. Its lead program, DM199 (rinvecalinase alfa; rhKLK1), is in Phase 2 for acute ischemic stroke (ReMEDy2 Phase 2/3); preeclampsia and fetal growth restriction (Phase 2). Its next catalyst on record is DM199 PE: Rat PK/pharmacologic activity study completion, then submission to FDA to support IND (October 2026).
Upcoming catalysts
- October 2026DM199 PE — Rat PK/pharmacologic activity study completion, then submission to FDA to support IND
we have initiated a pharmacokinetic (PK) (drug exposure) and pharmacologic activity study of DM199 in rats, expected to complete in October 2026
Next further out: DM199 PE — Global Phase 2 site activation commences (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DM199 - ReMEDy2 | acute ischemic stroke (Phase 2/3 adaptive, ~300-728 pts, enrolling) | protein/peptide | Phase 2 |
| DM199 - PE/FGR investigator-sponsored trial | preeclampsia (Parts 1a/1b/2) and fetal growth restriction (Part 3, enrollment began June 2026) | protein/peptide | Phase 2 |
| DM199 - global Phase 2 (North America/UK) | early-onset preeclampsia | protein/peptide | Phase 2 |
| DM300 (recombinant human ulinastatin) | severe acute pancreatitis | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.